

Butler, Jennie C

From: Bmauro2@aol.com
Sent: Tuesday, May 04, 1999 2:46 PM
To: FDADockets@test.oc.fda.gov
Cc: rcohen@acorda.com
Subject: 4-AP

To Whom It May Concern:

As the Resource Center Coordinator for the National Spinal Cord Injury Association I would encourage the FDA to restrict the availability of compounded drugs such as 4-AP. While individuals with spinal cord injury are in dire need and a quest for a cure, this does not mean that an unregulated, volatile compound should be made available. Studies have found that the compounded drug varies greatly in strength and can result in side effects such as seizures.

A reasonable compromise would be to allow Acorda therapeutics to grandfather in the individuals who are receiving the compounded drug to participate in the research that Acorda is currently conducting on fampridine.

Thank you for taking the time to read this email. On behalf of the members of NSCIA, we appreciate that the FDA is taking all steps possible to insure the health and safety of our members while advancing research in SCI.

Sincerely,
Bernadette F. Mauro
Resource Center Coordinator
National Spinal Cord Injury Association

98N-0182

C127